Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Michael A Postow

1-50 of 63 results

View this query on the Wikidata Query Service
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

scientific article (publication date: 2 July 2015)
Nivolumab plus ipilimumab in advanced melanoma

scientific article
Genetic basis for clinical response to CTLA-4 blockade in melanoma

scientific article (publication date: 4 December 2014)
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

scientific article (publication date: 21 May 2015)
Immunologic correlates of the abscopal effect in a patient with melanoma

scientific article (publication date: 8 March 2012)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

scientific article (publication date: 20 September 2014)
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

scientific article published on 17 August 2015
Immune modulation in cancer with antibodies

scientific article published on 30 October 2013
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

scientific article published on 19 September 2016
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

scientific article published on 01 August 2018
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.

scientific article published on 05 March 2015
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

scientific article published on March 7, 2014
Checkpoint blocking antibodies in cancer immunotherapy

scientific article published on October 23, 2013
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience

scientific article published on 02 August 2013
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

scientific article
On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

scientific article published on March 2015
Alternative transcription initiation leads to expression of a novel ALK isoform in cancer

scientific article published on 7 October 2015
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

scientific article published on 29 February 2016
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

scientific article published on 16 June 2015
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes

scientific article
Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma

scientific article published on July 25, 2013
Ipilimumab for patients with advanced mucosal melanoma

scientific article
Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement

scientific article published on 20 July 2015
Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes

scientific article
Immune checkpoint modulation: Rational design of combination strategies

scientific article published on January 10, 2015
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

scientific article
Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management

scientific article published on October 1, 2012
Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy

scientific article
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment

scientific article published on 15 December 2014
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

scientific article published on October 17, 2017
Immunomodulatory therapy for melanoma: Ipilimumab and beyond

scientific article published on March 1, 2013
Therapeutic Implications of KIT in Melanoma

scientific article published on March 1, 2012
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis

scientific article published on 10 June 2016
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.

scientific article
Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications

scientific article published on October 4, 2012
Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions

scientific article published on October 1, 2013
CTLA-4 antibodies: new directions, new combinations

scientific article published on November 1, 2014
Safety of Infusing Ipilimumab Over 30 Minutes

scientific article published on 29 June 2015
Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

scientific article published on 6 May 2014
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy

scientific article published on 3 November 2017
Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment

scientific article published on 08 April 2016
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

scientific article
Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma

Liver resection and ablation for metastatic melanoma: A single center experience

scientific article published on 12 June 2015
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma

scientific article published on 19 October 2016
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.

scientific article published on 16 November 2017
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

scientific article
Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

scientific article published in March 2015
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center

scientific article
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

Paulina is supported by:

About Paulina

Help